NA
INO icon

NewEdge Advisors’s Inovio Pharmaceuticals INO Stock Holding History

NewEdge Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58
Closed -$335 – 3962
2024
Q3 		$335 Buy
+58
New +$478 ﹤0.01% 3648
2024
Q1 		– Hold
0
– -$3 – 3891
2023
Q4 		– Hold
0
– – – 3730
2023
Q1 		– Sell
-4
Closed – – 3781
2022
Q4 		$0 Buy
+4
New +$91 ﹤0.01% 4145

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NewEdge Advisors's INO Position: Q4 2024 in Review

NewEdge Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 58 shares — an estimated $335 sold.

NewEdge Advisors first reported a position in INO in Q4 2022 and held it in 2 quarters. The position peaked at $335 in Q3 2024. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

  • NewEdge Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • NewEdge Advisors sold 58 Inovio Pharmaceuticals shares in Q4 2024, an estimated $335.
  • NewEdge Advisors first reported a position in Inovio Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's Inovio Pharmaceuticals position peaked at $335 in Q3 2024.
  • 104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.